Letters to the editor: April 3, 2006

Albert Dahan, MD, PhD, discusses recent data on Tris Pharma’s first-in-class dual-NMR agonist and how it will fit into the broader landscape of pain management therapies.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the federal level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

Researchers analyzed the outcomes of positive airway pressure therapy for Medicare beneficiaries with obstructive sleep apnea.

Jeremy Cundiff, PharmD, co-owner of Professional Pharmacy Group, joined Drug Topics to discuss Return Solutions and the company’s Rx Returns process.

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.